Sick Economics

Searching For Healthy Profits In The Stock Market

Sick Economics. Healthcare Investing Tips & Analysis. Big Pharma, Biotech, Medical Devices, Healthcare REITs & More.

SickEconomics.com is a sister site of SickDividends.com

SICK PICKS


Our favorite biotech shares and healthcare investments in today’s stock market. Highlighting companies that stand to profit through medical innovation, mismatches in share price to market potential, or just plain great economics. (Stocks may be owned by the Sick Economist, or other commentators on this page.)

CSBR

This emerging growth microcap has recently reached profitability along with impressive revenue gains. Champions Oncology, Inc. is making a name for itself by offering a wide range of research services to other pharmaceutical companies in the oncology field. Lately, the company has expanded into two promising new areas of growth; oncology research software, and new drug development. With the advent of precision cancer medicine and the explosion of new approaches to cancer treatment, Champions is well positioned to become a pillar of the oncology community.

finviz dynamic chart for CSBR

Click On Chart To Expand

MESO

This Australian company, listed on the NASDAQ stock exchange, seeks to treat a wide range of diseases through the creation of new kinds of cellular therapies. MESO currently has three phase III products in development. On August 14th, 2020, an FDA advisory committee voted 9-1 to recommend approval of Remestemcel-L as a novel treatment for graft vrs host disease in children. This vote puts Meso on track to launch its first FDA approved product in 2021. The company is also in advanced testing of new cellular therapies for severe Covid-19, lower back pain, and cardiovascular disease.

finviz dynamic chart for MESO

Click On Chart To Expand

MORF

Morphic Holding, Inc, is pioneering therapies that focus on integrins, a category of proteins that play a role in many chronic diseases of the autoimmune, cardiovascular and metabolic systems. The small biotech has recently expanded on a partnership with a Pharma Giant (ABBV). AbbVie has chosen to exercise a license option to develop Morphic’s αvβ6 integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications. We’ll be keeping a close eye on MORF over the coming months and years. If all goes well, MORF has a massive potential upside.

finviz dynamic chart for MORF

Click On Chart To Expand

BIOTECH INVESTING


Biotech investing means betting on scientific innovation. This space is dedicated to small cap biotech stocks, leading edge biotechnology research, and small stocks that have flown under the radar. Let’s talk about how you can turn innovation into profit.

THE SHEEP IN WOLF’S CLOTHING: WHAT BIOTECH INVESTORS NEED TO KNOW ABOUT HEALTHCARE REFORM

  The passage of the Inflation Reduction Act (IRA) has been hailed by many as…

3 BIOTECH TRENDS FOR 2023

  By The Sick Economist    “Smooth Seas Never Made a Strong Sailor”  2022 has…

NEW HORIZONS IN CANCER TREATMENT: WHAT INVESTORS NEED TO KNOW

By Subin Im, PharmD    With over 700 cancer drugs in late stages of development,…

HEALTHCARE SERVICES


Modern healthcare equities comprise an intricate ecosystem of healthcare service providers in addition to makers of medicines and devices. Investment in insurance companies, hospitals, clinics, and many other service providers have yielded substantial profits while helping millions of people.

HCA AND THE FUTURE OF HEALTHCARE

By Aidan Asbill, Equity Analyst   As we discussed in the last article, HCA Healthcare…

IS GOOGLE A HEALTHCARE COMPANY?

By Aidan Asbill, Securities Analyst    Google is one of the biggest technology companies in…

A CHAMPION OF DRUG DISCOVERY?

By Tammy Tran, Biotech Analyst   Champions Oncology ($CSBR) is a technology company that combines…

HEALTHCARE REITs


Healthcare Real Estate (REITs) are high yielding stocks in the healthcare industry. You can invest in nursing homes, medical office buildings and research labs. Learn a profitable and easy way to invest in healthcare real estate.

HIGH YIELD HEALTHCARE: AN INTERVIEW WITH JUSSI ASKOLA

Jussi Askola is the President of Leonberg Capital, a boutique investment research firm specializing in…

3 HEALTHCARE REITS FOR STEADY RETIREMENT INCOME

With the Fed reluctant to raise interest rates further, those in or near retirement may…

3 BEST HEALTHCARE VALUE STOCKS FOR 2019

Who doesn’t love a nice Christmas sale? Everyone loves to pick up some good bargains around the holidays. When we talk about spending money, every retailer in the world advertises their big deals. But when we talk about making money, those deals may not be so obvious…

CAPITAL EQUIPMENT


Robots, radiation cannons, and molecular imaging machines aren’t just the healthcare tech of the future; they are also the source of investor profit for many decades to come. Big machines can mean big profits for equity investors.

MEDICAL ROBOTICS: A PROFIT MACHINE?

By Tammy Tran, Equity Analyst    Although medical robotics has been a field that has…

WILL INTUITIVE SURGICAL BE PERMANENTLY CRIPPLED BY THE PANDEMIC?

Intuitive Surgical has revolutionized the minimally invasive, robotic-assisted surgical space with their FDA approved da…

LARRY CULP’S ART OF THE DEAL: 3 BUSINESS LESSONS FROM GE’S BIOPHARMACEUTICAL SALE

In a surprise move, GE has agreed to sell it’s BioPharmaceutical Division to Danaher for…

Subscribe To The Rx Newsletter

sick economics

You understand that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person. You further understand that none of the bloggers, information providers, app providers, or their affiliates are advising you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. To the extent that any of the content published on the Site may be deemed to be investment advice or recommendations in connection with a particular security, such information is impersonal and not tailored to the investment needs of any specific person. You understand that an investment in any security is subject to a number of risks, and that discussions of any security published on the Site will not contain a list or description of relevant risk factors.

The Site is not intended to provide tax, legal, insurance or investment advice, and nothing on the Site should be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by Sick Economics or any third party. You alone are solely responsible for determining whether any investment, security or strategy, or any other product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. You should consult an attorney or tax professional regarding your specific legal or tax situation.

ACCEPT